Aceso Life Sci <474> discloseable transaction disposal of shares in Future Data

Aceso Life Science Group Limited (HKEX: 474) has recently entered into a significant cross-shareholding agreement with Imagi Fin Group Limited (IFGL), a subsidiary of Imagi International Holdings (HK: 0585), marking a strategic development in its diversified business portfolio. Under the terms of the transaction, Aceso subscribed for new shares in IFGL for a total consideration of HK$167.32 million, while also allotting 1,476,350,000 of its own shares to IFGL. The share-swap agreement value is approximately HK$177.16 million.

The subscription price for Aceso’s shares was set at HK$0.12 per share, determined through an asset-based valuation method that considered IFGL’s net asset value and market conditions as of 30 November 2025. Adjustments were made for factors such as expected credit losses, market prices of listed securities, and a 9.88% discount for lack of marketability in certain assets.

Following the transaction, Imagi International Holdings’ direct stake in IFGL will decrease to approximately 79%, while IFGL will hold a 16.67% stake in Aceso, making it a substantial shareholder under HKEX rules. This cross-shareholding arrangement is expected to enhance both companies’ balance sheets and investor bases, while reinforcing their financial credibility in the competitive Hong Kong market.